You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 12, 2025

Details for New Drug Application (NDA): 208464

✉ Email this page to a colleague

NDA 208464 describes VEMLIDY, which is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the VEMLIDY profile page.

The generic ingredient in VEMLIDY is tenofovir alafenamide fumarate. There are forty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tenofovir alafenamide fumarate profile page.

Summary for 208464

Tradename:	VEMLIDY
Applicant:	Gilead Sciences Inc
Ingredient:	tenofovir alafenamide fumarate
Patents:	3

Pharmacology for NDA: 208464

Mechanism of Action	Nucleoside Reverse Transcriptase Inhibitors

Suppliers and Packaging for NDA: 208464

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
VEMLIDY	tenofovir alafenamide fumarate	TABLET;ORAL	208464	NDA	Gilead Sciences, Inc.	61958-2301	61958-2301-1	30 TABLET in 1 BOTTLE, PLASTIC (61958-2301-1)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	EQ 25MG BASE
Approval Date:	Nov 10, 2016	TE:	AB	RLD:	Yes
Regulatory Exclusivity Expiration:	Oct 17, 2025
Regulatory Exclusivity Use:	NEW PATIENT POPULATION
Patent:	⤷ Get Started Free	Patent Expiration:	Jul 7, 2025	Product Flag?		Substance Flag?		Delist Request?	Y
Patent:	⤷ Get Started Free	Patent Expiration:	Feb 15, 2033	Product Flag?		Substance Flag?		Delist Request?	Y

Expired US Patents for NDA 208464

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Gilead Sciences Inc	VEMLIDY	tenofovir alafenamide fumarate	TABLET;ORAL	208464-001	Nov 10, 2016	⤷ Get Started Free	⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.